Sign in
Taking people in United StatesPhase 4

Two ways of taking progesterone in girls with Turner syndrome on hormone therapy

Compares progesterone taken in cycles versus daily in adolescents with Turner syndrome.

Key facts

Who runs it
Children's Mercy Hospital Kansas City
Where
Kansas City, United StatesSee the site
Trial code
Registry title
Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
Status
Recruiting
Phase
Phase 4
People taking part
40 people, planned
Started
31 Jul 2025
Expected to end
31 Jul 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Micronized progesterone 200 MG
  • Micronized Progesterone 100 MG
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for girls and young women with Turner Syndrome and primary ovarian insufficiency (ovaries that stopped working early) who take estrogen hormone therapy. It compares two ways of taking progesterone.

Age
12 Years to 20 Years
Sex
Female only
Disease stage
Turner Syndrome with primary ovarian insufficiency. Must have already had a first period.
Earlier treatment
Must be prescribed adult doses of estradiol: 50-200μg/day through the skin or 2-4mg/day by mouth. Cannot have had depot medroxyprogesterone injection within one year before joining.

Main reasons for not taking part

  • Being sexually active and wanting birth control
  • Having a levonorgestrel-releasing intrauterine device (IUD) in place
  • Having an etonogestrel arm implant in place
  • Depot medroxyprogesterone within one year before joining
  • Not speaking English or Spanish

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency
  • Prescribed adult dosing* of transdermal or oral estradiol for estrogen replacement therapy; *Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg/day of transdermal estradiol, or (i.e. 50-200μg/day of transdermal estradiol or 2-4mg/day oral estradiol)
  • Have achieved menarche

Who cannot take part

  • Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place
  • Having received depot medroxyprogesterone within one year prior to study recruitment
  • Disclosure of sexual activity and desire for contraception
  • Non-English or non-Spanish speaking

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 20 years old?

Where in United States

  • Children's Mercy HospitalKansas City, United StatesContact: Allie RanalloTaking people

About the trial

What the trial wants to find out

This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).

The 2 groups in the trial

  • Sequential progesterone supplementationExisting treatment, for comparison

    Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle.

    Treatment: Micronized progesterone 200 MG

  • Continuous progesterone supplementation:Existing treatment, for comparison

    Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.

    Treatment: Micronized Progesterone 100 MG

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome: A Non-randomized Prospective Trial (The BOOST Study)
Plain-language title
Two ways of taking progesterone in girls with Turner syndrome on hormone therapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06834594, who can take part
Record updated
25 August 2026